As an RNAi focused pharmaceutical company, Arrowhead understands the important role genes can play in rare diseases such as hypertriglyceridemia and FCS. Accessing confidential, trusted, affordable, and timely genetic testing and counseling services can be a challenge for patients and providers for a variety of reasons. By providing no-cost genetic testing, Arrowhead hopes to further demonstrate its ongoing commitment to engagement with the FCS patient and caregiver communities as studies continue to find effective treatments and broaden awareness of this rare, but impactful disease.
